NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

SRPT

Sarepta Therapeutics Inc

May 14 • 04:00PM ET

35.74

Dollar change -0.46
Percentage change -1.27	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BMRN ALNY IONS PFE PTCT EXEL PRTA BLUE RDUS

| Held by: VTI VB IJH VXF VBK XBI MDY FBT IBB IJK

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.58	Insider Own	6.07%	Shs Outstand	98.25M	Perf Week	-2.67%
Market Cap	3.51B	Forward P/E	4.80	EPS next Y	7.45	Insider Trans	-0.24%	Shs Float	92.31M	Perf Month	-34.58%
Income	-248.39M	PEG	-	EPS next Q	0.92	Inst Own	87.83%	Short Float	7.26%	Perf Quarter	-67.45%
Sales	2.23B	P/S	1.57	EPS this Y	-171.95%	Inst Trans	0.21%	Short Ratio	2.20	Perf Half Y	-70.61%
Book/sh	11.63	P/B	3.07	EPS next Y	574.69%	ROA	-7.43%	Short Interest	6.70M	Perf Year	-72.89%
Cash/sh	5.32	P/C	6.72	EPS next 5Y	61.61%	ROE	-23.61%	52W Range	34.90 - 173.25	Perf YTD	-70.61%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-9.99%	52W High	-79.37%	Beta	0.61
Dividend TTM	-	Quick Ratio	2.46	Sales past 5Y	38.19%	Gross Margin	80.07%	52W Low	2.41%	ATR (14)	4.18
Dividend Ex-Date	-	Current Ratio	4.02	EPS Y/Y TTM	-1881.09%	Oper. Margin	-5.25%	RSI (14)	22.47	Volatility	8.44% 7.09%
Employees	1372	Debt/Eq	1.18	Sales Y/Y TTM	59.15%	Profit Margin	-11.12%	Recom	1.44	Target Price	102.48
Option/Short	Yes / Yes	LT Debt/Eq	1.18	EPS Q/Q	-1361.33%	Payout	0.00%	Rel Volume	1.71	Prev Close	36.20
Sales Surprise	8.35%	EPS Surprise	-43.44%	Sales Q/Q	80.15%	Earnings	May 06 AMC	Avg Volume	3.05M	Price	35.74
SMA20	-31.48%	SMA50	-45.71%	SMA200	-67.23%	Trades		Volume	5,203,253	Change	-1.27%

Date	Action	Analyst	Rating Change	Price Target Change
May-08-25	Downgrade	Evercore ISI	Outperform → In-line	$50
Apr-11-25	Initiated	Wells Fargo	Overweight	$115
Apr-02-25	Upgrade	H.C. Wainwright	Sell → Neutral	$75
Mar-31-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$161 → $87
Feb-11-25	Initiated	Deutsche Bank	Hold	$136
Nov-27-24	Reiterated	Needham	Buy	$205 → $202
Nov-25-24	Initiated	H.C. Wainwright	Sell	$80
Nov-07-24	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$152 → $167
Oct-21-24	Initiated	Jefferies	Buy	$165
Oct-10-24	Resumed	Raymond James	Outperform	$150
Jul-29-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$182
Jun-26-24	Downgrade	Citigroup	Buy → Neutral	$172 → $176
May-31-24	Initiated	Piper Sandler	Overweight	$157
May-28-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$157 → $142
May-14-24	Upgrade	Oppenheimer	Perform → Outperform	$180
Jan-31-24	Initiated	BMO Capital Markets	Outperform	$170
Dec-13-23	Resumed	Citigroup	Buy	$113
Dec-12-23	Initiated	Deutsche Bank	Buy	$109
Nov-21-23	Initiated	Wedbush	Outperform	$224
Oct-31-23	Downgrade	Oppenheimer	Outperform → Perform

Show Previous Ratings

Today 08:30AM	Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn't Ignore (MarketBeat)
May-13-25 09:25AM	Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy (Business Wire)
04:14AM	2 Stocks Near Their 52-Week Lows That Still Aren't Worth Buying (Motley Fool)
May-11-25 04:41PM	Sarepta Therapeutics, Inc. (SRPT): Among Billionaire Glenn Russell Dubin's Stock Picks with Huge Upside Potential (Insider Monkey)
May-09-25 12:01PM	Trump announces trade deal, BoE lowers Bank Rate: Morning Buzz (TipRanks)
08:48AM	Loading…
08:48AM	Is Sarepta Therapeutics, Inc. (SRPT) The Best Stock That Will Bounce Back? (Insider Monkey)
May-08-25 04:30PM	Sarepta Therapeutics to Present at the BofA Securities Health Care Conference (Business Wire)
10:36AM	Sarepta price target lowered to $125 from $183 at Needham (TipRanks)
05:01AM	Why Sarepta Therapeutics, Inc. (SRPT) Nosedived on Wednesday (Insider Monkey)
May-07-25 04:17PM	The 'Double Whammy' That Sent Sarepta Stock To An Eight-Year Low (Investor's Business Daily) -21.45%
02:14PM	Sarepta: ELEVIDYS DMD Treatment Setback Brings Downgrade To Hold Rating (Seeking Alpha)
01:32PM	Sarepta Therapeutics Stock Plunges on Guidance Cut. Its Moneymaker Is Under Fire. (Barrons.com)
12:14PM	Sarepta Therapeutics: Lowered Elevidys Guidance Warrant Ratings Downgrade (Seeking Alpha)
11:25AM	Nebius Group, Oscar Health Q1 earnings, Sarepta cuts outlook (Yahoo Finance Video)
09:41AM	Q1 2025 Sarepta Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
08:31AM	Loading…
08:31AM	SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut (Zacks)
07:46AM	Sarepta stock plummets as lower sales outlook adds to gloom over FDAs new biologics hire (BioPharma Dive)
07:46AM	Sarepta shares plummet as lower sales outlook adds to gloom over FDAs new biologics hire (BioPharma Dive)
07:29AM	Sarepta shares fall amid FDAs CBER appointment and weak Elevidys sales (Pharmaceutical Technology)
03:19AM	Sarepta Therapeutics Inc (SRPT) Q1 2025 Earnings Call Highlights: Robust Revenue Growth Amidst ... (GuruFocus.com)
May-06-25 10:41PM	Sarepta Therapeutics, Inc. (SRPT) Q1 2025 Earnings Call Transcript (Seeking Alpha) -26.56%
06:00PM	Compared to Estimates, Sarepta Therapeutics (SRPT) Q1 Earnings: A Look at Key Metrics (Zacks)
05:35PM	Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments (Business Wire)
May-05-25 08:00AM	Biohaven Is Now A Compelling Contrarian Play Before Troriluzole's FDA Verdict (Seeking Alpha)
04:44AM	CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts (Seeking Alpha)
May-04-25 06:46AM	Oppenheimer Predicts Up to ~840% Surge for These 2 Strong Buy Stocks (TipRanks)
May-01-25 12:36AM	1 of Wall Street's Favorite Stock on Our Buy List and 2 to Approach with Caution (StockStory)
Apr-30-25 10:01AM	Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-29-25 08:24PM	Why Sarepta Therapeutics, Inc. (SRPT) is Among the Best Oversold NASDAQ Stocks to Buy Right Now (Insider Monkey)
10:01AM	Loading…
10:01AM	Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Apr-24-25 07:54AM	Sarepta Therapeutics (SRPT): Among Billionaire George Soros' Small-Cap Stocks with Huge Upside Potential (Insider Monkey)
Apr-22-25 08:30AM	Sarepta Therapeutics to Announce First Quarter 2025 Financial Results (Business Wire) +7.39%
Apr-21-25 10:19PM	Is Sarepta Therapeutics, Inc. (SRPT) the Most Promising Long-Term Stock According to Analysts? (Insider Monkey)
04:09PM	Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost (Investor's Business Daily)
Apr-16-25 07:32AM	SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies (Zacks)
Apr-15-25 08:30AM	Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs (Business Wire)
Apr-11-25 02:13PM	Keros Therapeutics: Strategic Alternatives Could Bring About Value Creation (Seeking Alpha)
Apr-10-25 05:00AM	The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb (Zacks) -9.60%
Apr-09-25 01:45PM	Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More (Zacks) +12.88%
Apr-08-25 04:50PM	Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space (Seeking Alpha) -5.92%
07:30AM	Can Solid Biosciences Challenge Sarepta in the DMD Market? (MarketBeat)
05:14AM	3 Reasons to Avoid SRPT and 1 Stock to Buy Instead (StockStory)
Apr-07-25 08:09AM	4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street (Motley Fool)
07:21AM	Sarepta and Roche aim to resume paused Elevidys trials following patient death (Clinical Trials Arena)
Apr-04-25 10:38AM	Sarepta Therapeutics Stock Falls as Some Trials Halted After Patient Death (Investopedia) -7.13%
09:25AM	Sarepta price target lowered to $183 from $202 at Needham (TipRanks)
08:44AM	Sarepta Therapeutics Provides Update on ELEVIDYS (Business Wire)
07:29AM	SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy (Zacks)
Apr-03-25 04:27PM	Sarepta Dives On 'Another Unfortunate Development' For Its Gene Therapy (Investor's Business Daily) -6.18%
03:37PM	BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion (Seeking Alpha)
03:23PM	Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death (Benzinga)
08:58AM	Sarepta Plunges After EMA Puts Gene Therapy Studies On Hold Following Teen's Death (Investor's Business Daily)
07:19AM	Roche halts testing of Sarepta Duchenne gene therapy in Europe (BioPharma Dive)
Apr-01-25 12:40PM	Sarepta price target lowered to $179 from $210 at BofA (TipRanks)
12:16PM	Rocket acquires Mr. Cooper, Musks xAI acquires X: Morning Buzz (TipRanks)
12:15PM	3 Market Predictions For April (Seeking Alpha)
11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks)
07:23AM	Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr. (Zacks)
Mar-31-25 05:54PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.36%
04:12PM	Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.'s 'Misinformation And Lies' (Investor's Business Daily)
01:29PM	Why Sarepta Therapeutics (SRPT) Stock Is Nosediving (StockStory)
11:05AM	Biotech Investors Rush for the Exits After FDA Official Resigns: Heard on the Street (The Wall Street Journal)
09:45AM	Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns (Investor's Business Daily)
09:31AM	Moderna, Novavax Stocks Fall After Top FDA Vaccine Official Forced Out (The Wall Street Journal)
Mar-29-25 04:17PM	Is Sarepta Therapeutics (SRPT) the Best Mid Cap Biotech Stock to Buy? (Insider Monkey)
Mar-28-25 11:30AM	Sarepta Therapeutics (SRPT) Down 30.3% Since Last Earnings Report: Can It Rebound? (Zacks)
09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
Mar-26-25 12:31PM	5 Reasons To Buy Regenxbio Right Now (SeekingAlpha)
10:17AM	The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (SeekingAlpha)
Mar-24-25 08:25AM	How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion (Zacks)
Mar-23-25 09:30AM	Is This Stock a Buy After a Massive 20% Drop in 1 Day? (Motley Fool)
07:18AM	Wall Street Week Ahead (SeekingAlpha)
Mar-21-25 04:46AM	The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics (Zacks)
Mar-20-25 01:55PM	Sarepta: Should Investors Run For The Exit? (SeekingAlpha) -8.15%
12:45PM	Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More (Zacks)
09:05AM	Invesco Health Care Fund Q4 2024 Commentary (SeekingAlpha)
01:58AM	Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.7% Jump Turn into More Strength? (Zacks)
Mar-19-25 09:02PM	Why Sarepta Therapeutics Inc. (SRPT) Went Up On Wednesday? (InsiderMonkey) +8.74%
01:38PM	SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion (Zacks)
09:28AM	Why Sarepta Therapeutics Inc. (SRPT) Crashed On Tuesday? (Insider Monkey)
08:57AM	Company News for Mar 19, 2025 (Zacks)
Mar-18-25 04:01PM	Sarepta's 27% Sell-Off Is 'Overblown,' 'Overdone' And 'Overly Bearish.' Here's Why It Happened. (Investor's Business Daily) -27.44%
11:55AM	Why Sarepta Therapeutics (SRPT) Shares Are Sliding Today (StockStory)
10:42AM	Patient dies following muscular dystrophy gene therapy, Sarepta reports (Associated Press Finance)
10:29AM	Sarepta Therapeutics Stock Sinks After Company Says Patient Taking Its Drug Dies (Investopedia)
10:21AM	Gene-Therapy Maker Sarepta Tanks After Patient Death (The Wall Street Journal)
10:21AM	Gene Therapy Maker Tanks After Patient Death (The Wall Street Journal)
10:17AM	Patient Dies After Receiving Sareptas Gene Therapy (Barrons.com)
10:08AM	Sarepta Therapeutics Plummets 23% After Gene Therapy Recipient Dies (Investor's Business Daily)
09:29AM	Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges (Benzinga)
Mar-04-25 04:03AM	Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4 (StockStory)
Feb-28-25 10:20AM	Sarepta price target lowered to $210 from $217 at BofA (TipRanks)
09:00AM	Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program (Business Wire)
Feb-27-25 08:50AM	Q4 2024 Sarepta Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
02:19AM	Sarepta Therapeutics Inc (SRPT) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Feb-26-25 11:00PM	Sarepta Therapeutics (SRPT) Q4 2024 Earnings Call Transcript (Motley Fool)
05:25PM	Sarepta Therapeutics (SRPT) Lags Q4 Earnings Estimates (Zacks)
04:36PM	Sarepta Therapeuticss (NASDAQ:SRPT) Q4: Beats On Revenue (StockStory)
04:23PM	Sarepta Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nicaise Claude	Director	Mar 12 '25	Option Exercise	25.18	9,746	245,404	30,303	Mar 13 08:00 PM
Nicaise Claude	Director	Mar 12 '25	Sale	99.64	2,491	248,203	27,812	Mar 13 08:00 PM
Nicaise Claude	Director	Mar 12 '25	Proposed Sale	99.65	2,491	248,226		Mar 12 05:33 PM
Estepan Ian Michael	Chief Financial Officer	Jan 29 '25	Option Exercise	12.00	15,800	189,600	49,496	Jan 31 08:30 PM
Wigzell Hans Lennart Rudolf	Director	Dec 12 '24	Option Exercise	13.71	10,500	143,955	33,340	Dec 16 08:00 PM
Wigzell Hans Lennart Rudolf	Director	Dec 12 '24	Sale	124.84	10,500	1,310,820	22,840	Dec 16 08:00 PM
Wigzell Hans Lennart Rudolf	Director	Dec 12 '24	Proposed Sale	124.80	10,500	1,310,400		Dec 12 05:06 PM
Boor Kathryn Jean	Director	Dec 05 '24	Sale	125.55	1,636	205,400	5,880	Dec 06 08:00 PM
Boor Kathryn Jean	Director	Dec 05 '24	Proposed Sale	125.55	1,636	205,400		Dec 05 04:18 PM
Estepan Ian Michael	Chief Financial Officer	Aug 30 '24	Sale	137.36	5,985	822,100	33,946	Sep 03 08:00 PM
Estepan Ian Michael	Officer	Aug 30 '24	Proposed Sale	137.37	5,985	822,130		Aug 30 05:03 PM
Chambers Michael Andrew	Director	Aug 16 '24	Buy	133.80	37,038	4,955,728	284,034	Aug 20 08:00 AM
BEHRENS M KATHLEEN	Director	Jul 03 '24	Option Exercise	13.90	15,000	208,500	191,839	Jul 08 08:00 PM
Brown Ryan Edward	EVP, General Counsel	Jun 25 '24	Option Exercise	62.77	23,500	1,475,095	56,086	Jun 25 08:00 PM
Brown Ryan Edward	EVP, General Counsel	Jun 25 '24	Sale	161.61	38,957	6,296,029	17,129	Jun 25 08:00 PM
Arif Bilal	Chief Tech Ops Officer	Jun 24 '24	Sale	163.08	7,859	1,281,621	21,261	Jun 25 08:00 PM
Arif Bilal	Chief Tech Ops Officer	Jun 25 '24	Sale	163.23	3,898	636,271	17,363	Jun 25 08:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SRPT

Sarepta Therapeutics Inc

Upgrade your FINVIZ experience